News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Celgene Corp $CELG Chart Signals Trouble
Shares of Celgene Corp (CELG) have a nasty chart and pro traders are alerting investors. The stock price is currently forming a classic bear flag pattern. To make matters worse, the daily 20, 50 and 200 moving averages are just above current price and turning lower. This signals a likely fall on Celgene Corp in the coming weeks to as low as $75.00.
Gareth Soloway
InTheMoneyStocks
Breakout Alert: Celgene $CELG
Shares of Celgene Corp (CELG) are beginning to breakout on the daily stock chart. This pattern setup is fantastic as money is beginning to flow from over-bought sectors to under-bought sectors. In a market priced to perfection, the biotechnology stocks have drastically lagged. Their valuations are extremely attractive compared to an Amazon (AMZN) and Netflix (NFLX). The Celgene stock chart has formed a beautiful bull flag just off the 52 week lows. Today, the breakout is beginning as the stock is up over 2% and cracking the upper band trend line. Look for an upside target of $86 in the near-term.
Gareth Soloway
InTheMoneyStocks
Celgene Corp $CELG Is Trending Down, Know This Level
Leading biotechnology stock Celgene Corp (NASDAQ:CELG) has been trending lower since October 2017. At that time, the stock traded as high as $147.17 a share. Today, CELG stock is trading around the $87.00 area. Traders can easily see how this stock has fallen from grace over the past five months. The stock is now trading below its 50 and 200 week moving averages, this is a very negative chart formation. The stock should now find some solid support around the $82.75 area. This is a major retrace level where the stock could bounce from the current oversold condition.
Nicholas Santiago
InTheMoneyStocks
This Leading Biotechnology Level Should Be On The Radar
One of the leading biotechnology stocks in the world is Celgene Corporation (NASDAQ:CELG). This company discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases. Celgene stock topped out on March 17th at $127.64 a share. Today, Celgene stock is trading at $116.97 a share. Traders can easily see that this leading biotechnology stock has been trending lower on the charts lately. The stock now has major chart support around the $110.00 level. This is an area where the major institutional money supported the equity back in December 2016. Often, old pivot levels will serve as major chart support when retested.
Nicholas Santiago
InTheMoneyStocks
Cowen and Co reiterated Celgene at Outperform. Valuation models show nice Upside:
Upside Analysis
|
Followers
|
45
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
344
|
|
Created
|
01/23/06
|
Type
|
Free
|
| Moderators | |||
Company Information:
Celgene Corp.
86 Morris Avenue
Summit, NJ 07901
Phone: (908) 673-9000
CIK
0000816284
Celgene Corporation, a publicly traded company…
Committed to Improving the Lives of Patients Worldwide
Celgene is a multinational biopharmaceutical company committed to improving the lives of patients worldwide.
At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our mission as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.
There are numerous clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocyte leukemia (CLL), non-Hodgkin's lymphoma (NHL), glioblastoma, and ovarian, pancreatic and prostate cancer.
As committed as we are to clinical accomplishment, we are equally committed to
| Our portfolio of services and pharmaceutical products in the U.S. include: | ||
Products | ||
| ALKERAN® (melphalan) tablets | ||
| ALKERAN® (melphalan) for injection | ||
| REVLIMID® (lenalidomide) | ||
| THALOMID® (thalidomide) | ||
| VIDAZA® (azacitidine for injection) | ||
Services | ||
| LifebankUSA (placental and cord blood banking) | ||
Press Releases:
http://ir.celgene.com/phoenix.zhtml?c=111960&p=irol-news&nyo=0
Filings:
Transfer Agent:
American Stock Transfer & Trust Company
59 Maiden Lane
New York 10038
Last update 4.12.2010
All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
Rules of the board according to IHUB:
http://www.investorshub.com/boards/complex_terms.asp
